One trend in psychosomatic medicine is establishing integrated care in both the private and public sectors. For example, there is a mandate in the VA system to integrate primary and mental health care.Abstract Teaser ...[Read More]

On February 5, Teva Pharmaceutical announced the enrollment of the first patient in the MODERATO study, a phase 4 clinical study designed to evaluate the effect of Azilect (rasagiline tablets) on cognitive function in adults with Parkinson’s disease who also have mild cognitive impairment (PD-MCI). ...[Read More]

Eli Lilly and Company announced negative clinical trial results in July from a study known as H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for treatment of acute exacerbations of schizophrenia. Lilly said the drug did not separate from placebo in the primary efficacy endpoint in either the overall or predefined ...[Read More]